Cocrystal Pharma Advances Promising Influenza A Drug
Company Announcements

Cocrystal Pharma Advances Promising Influenza A Drug

Cocrystal Pharma Inc (COCP) has issued an update.

Cocrystal Pharma, Inc. has announced progress in the clinical development of their CC-42344 drug candidate, which shows promise as a treatment for both pandemic and seasonal influenza A. The update was shared in a recent press release by the company.

For a thorough assessment of COCP stock, go to TipRanks’ Stock Analysis page.

Related Articles
Brian AndersonCocrystal Pharma (COCP) Q3 Earnings Cheat Sheet
TipRanks Auto-Generated NewsdeskCocrystal Pharma Advances Antiviral Drug Development
TheFlyCocrystal Pharma highlights approach to antiviral drug candidates
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App